ArticleCaspian journal of internal medicine2022

Two trade names of deferasirox (Osveral® and Exjade®) in reduction of iron overload parameters in major beta-thalassemia patients: A randomized open labeled clinical trial.

Mohammadreza Rafati et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.